Bharat Biotech completes recruitment of 13,000 volunteers for phase III clinical trial trials of Covaxin

Bharat Biotech on Tuesday announced recruitment of 13,000 volunteers and continued progress towards achieving the goal of 26,000 participants for the phase III clinical trial clinical trials of its COVID-19 vaccine ‘Covaxin’ across multiple sites in India.

Covaxin has been evaluated in approximately 1,000 subjects in phase I clinical trial and phase II clinical trial clinical trials, with promising safety and immunogenicity results, Bharat Biotech said during a statement.

The indigenously developed COVID-19 vaccine has been developed together with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), it added.

Heidi Phillips

Leave a Reply

Your email address will not be published. Required fields are marked *